<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548404" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548404/" /><meta name="ncbi_pagename" content="Amodiaquine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Amodiaquine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Amodiaquine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/02/02" /><meta name="citation_pmid" content="31643723" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548404/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Amodiaquine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/02/02" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548404/" /><meta name="description" content="Amodiaquine is an aminoquinoline used for the therapy of malaria. Amodiaquine has been linked to severe cases of acute hepatitis which can be fatal, for which reason it is recommended for use only as treatment and not for prophylaxis against malaria." /><meta name="og:title" content="Amodiaquine" /><meta name="og:type" content="book" /><meta name="og:description" content="Amodiaquine is an aminoquinoline used for the therapy of malaria. Amodiaquine has been linked to severe cases of acute hepatitis which can be fatal, for which reason it is recommended for use only as treatment and not for prophylaxis against malaria." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548404/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Amodiaquine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548404/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89ADD204652321000000000894028D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548404_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548404_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Amlodipine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Amoxapine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548404_"><span class="title" itemprop="name">Amodiaquine</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 2, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Amodiaquine.OVERVIEW"><h2 id="_Amodiaquine_OVERVIEW_">OVERVIEW</h2><div id="Amodiaquine.Introduction"><h3>Introduction</h3><p>Amodiaquine is an aminoquinoline used for the therapy of malaria. Amodiaquine has been linked to severe cases of acute hepatitis which can be fatal, for which reason it is recommended for use only as treatment and not for prophylaxis against malaria.</p></div><div id="Amodiaquine.Background"><h3>Background</h3><p>Amodiaquine (am" oh dye' a kwin) is a synthetic aminoquinoline that acts by binding to the protozoal or parasitic DNA and preventing DNA and RNA production and subsequent protein synthesis. It is active against the asexual erythrocytic forms of Plasmodium species. Amodiaquine is related in structure to chloroquine, and highly chloroquine-resistant P. falciparum is also resistant to amodiaquine. Amodiaquine remains a useful agent for treating falciparum malaria, but because of its potential for causing hepatotoxicity, it is no longer used for antimalarial prophylaxis. Amodiaquine is available in tablets of 150 to 600 mg in generic forms and under the brand names Camoquin and Flavoquine. The recommended dosage is 10 mg/kg of amodiaquine base once daily for 3 days usually in combination with other antimalarial agents. Common side effects of amodiaquine include nausea, diarrhea, skin rash and itching.</p></div><div id="Amodiaquine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Amodiaquine has been linked to serum aminotransferase elevations in a small proportion of patients (1%). More importantly, there have been multiple reports of idiosyncratic acute liver injury due to amodiaquine. The onset of injury is usually within 1 to 4 months and is often associated with agranulocytosis. The pattern of serum enzyme elevations is most frequently hepatocellular, and symptoms resembling acute viral hepatitis are typical. Features of hypersensitivity are uncommon, as are autoantibodies. The hepatitis can be severe, and several fatal instances or cases requiring emergency liver transplantation have been reported. The frequency of serious hepatic injury is estimated to be ~1:15,000. Because of the risks of agranulocytosis and liver injury, amodiaquine is no longer recommended for use as prophylaxis against malaria and is used largely for therapy in endemic areas outside of the United States. General recommendations on the therapy of malaria including specific details on diagnosis, management, drug dosage and safety are available at the CDC website: http://www.cdc.gov/malaria/.</p><p>Likelihood score: A (well established cause of clinically apparent liver injury).</p></div><div id="Amodiaquine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which amodiaquine causes liver injury is unknown, clinical factors and testing for serum antibodies suggest an idiosyncratic immunological reaction to a hepatic metabolite may be responsible. Amodiaquine is extensively metabolized by the liver to metabolites that are excreted in the urine.</p></div><div id="Amodiaquine.Outcome_and_Management"><h3>Outcome and Management</h3><p>There does not seem to be cross reactivity to hepatic injury among the various antimalarial agents and switching to other drug can be done.</p><p>Drug Class: <a href="/books/n/livertox/AntimalarialAgents/">Antimalarial Agents</a></p></div></div><div id="Amodiaquine.PRODUCT_INFORMATION"><h2 id="_Amodiaquine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Amodiaquine.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Amodiaquine &#x02013; Generic, Camoquin&#x000ae;, Flavoquine&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antimalarial Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Amodiaquine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Amodiaquine.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Amodiaquine_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Amodiaquine.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548404/table/Amodiaquine.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Amodiaquine.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Amodiaquine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Amodiaquine.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Amodiaquine.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Amodiaquine.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Amodiaquine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Amodiaquine</td><td headers="hd_h_Amodiaquine.T1_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970939" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">86-42-0</a></td><td headers="hd_h_Amodiaquine.T1_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C20-H22-Cl-N3-O</td><td headers="hd_h_Amodiaquine.T1_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548404/bin/Amodiaquine_Structure.jpg" alt="Chemical Structure for Amodiaquine" /></div></td></tr></tbody></table></div></div></div><div id="Amodiaquine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Amodiaquine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 02 February 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Amodiaquine.R1">Zimmerman HJ. Antiprotozoal agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 623-5.<div><i>(Expert review of hepatotoxicity published in 1999; amodiaquine has been associated with many cases of severe hepatitis, some fatal, with onset ranging from a few days to as long as one year after starting).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R2">Vinetz JM, Clain J, Bounkeua V, Eastman RT, Fidock D. Chemotherapy of malaria. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1383-418.<em>
</em><div><i>(Textbook of pharmacology and therapeutics; amodiaquine is a congener of chloroquine that is no longer recommended because of its toxicity).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R3">Glick L. Fatal agranulocytosis during treatment with amodiaquine. Br Med J 1957; 1: 932.  [<a href="/pmc/articles/PMC1973250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1973250</span></a>] [<a href="/pubmed/13413258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13413258</span></a>]<div><i>(53 year old woman with photosensitive rash was given amodiaquine for 8 weeks and developed fatal agranulocytosis and jaundice; on autopsy, the liver was enlarged and had a nutmeg appearance).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R4">Pomeroy H, Warren C, Mills D, Clark GM. The effect of amodiaquin (Camoquin) on the course of rheumatoid arthritis. Arthritis Rheum 1959; 2: 396-402.  [<a href="/pubmed/14433954" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14433954</span></a>]<div><i>(Placebo controlled crossover study of amodiaquine in 7 elderly patients with rheumatoid arthritis; mentions in discussion that 2 of 32 patients receiving amodiaquine at their institution developed jaundice 4 and 16 weeks after starting, one dying of liver failure).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R5">Bepler CR, Baier HN, McCracken S, Rentschler CL, Rogers FB, Lansbury J. A 15-month controlled study of the effects of amodiaquin (Camoquin) in rheumatoid arthritis. Arthritis Rheum 1959; 2: 403-13.  [<a href="/pubmed/13799077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13799077</span></a>]<div><i>(Placebo controlled crossover study of amodiaquine in 14 patients with rheumatoid arthritis; 400 mg dose was not tolerated; long term 50 mg daily doses led to jaundice in 2, Alk P elevations in 2, and AST in 4 patients [peak levels 100 U/L]).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R6">Perry HO, Bartholomew LG, Hanlon DG. Nearly fatal reaction to amodiaquine. JAMA 1962; 179: 598-601.  [<a href="/pubmed/14485571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14485571</span></a>]<div><i>(33 year old man with systemic lupus developed fever and fatigue after 6 days of intermittent amodiaquine therapy with rash and neutropenia [bilirubin 2.3 mg/dL, AST 101 U/L], resolving rapidly with corticosteroid therapy; neutropenia lasted 2 weeks).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R7">Gillespie P, Wagner F. Amodiaquine agranulocytosis. Med J Aust 1977; 1: 298-9.  [<a href="/pubmed/859490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 859490</span></a>]<div><i>(26 year old woman on amodiaquine prophylaxis developed skin abscess and septicemia with white count of 300/&#x000b5;L and no neutrophils; liver tests were &#x0201c;consistent with hepatocellular damage&#x0201d;, but no specifics given).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R8">Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR, Edwards G, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; 1: 411-4.  [<a href="/pubmed/2868340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2868340</span></a>]<div><i>(7 cases of severe neutropenia [0-400/&#x000b5;L] after 3 to 13 weeks of amodiaquine therapy, lasting 3-20 days, all with recovery; some patients were jaundiced, but no specifics given).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R9">Hirschel B. Amodiaquine and hepatitis. Ann Intern Med 1986; 105: 467.  [<a href="/pubmed/3740693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3740693</span></a>]<div><i>(Mentions that there have been 20 cases of agranulocytosis [12 with hepatitis] in Switzerland among travelers taking amodiaquine, and describes two patients who acquired malaria despite the prophylaxis).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R10">Woodtli W, Vonmoos P, Siegrist P, Zollikofer H. [Amodiaquine-induced hepatitis with leukopenia]. Schweiz Med Wochenschr 1986; 116: 966-8. German.  [<a href="/pubmed/3764379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3764379</span></a>]<div><i>(Two cases; 40 and 55 year old travelers with fever and dark urine arising 4 and 8 weeks after starting amodiaquine [bilirubin 0.8 and 6.0 mg/dL, ALT 320 and 50 U/L, Alk P 171 and 186 U/L], resolving within 1-2 months of stopping and recurring in both with rechallenge).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R11">Larrey D, Castot A, P&#x000eb;ssayre D, Merigot P, Machayekhy JP, Feldmann G, Lenoir A, et al. Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 1986; 104: 801-3.  [<a href="/pubmed/2871789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2871789</span></a>]<div><i>(Report of 7 cases of liver injury due to amodiaquine prophylaxis; 6 men and 1 woman, ages 34-64 years, taking 200-800 mg/week for 4 to 15 weeks, no eosinophilia or rash; 4 anicteric cases had fatigue and abdominal pain [ALT 3-6.5 times ULN, Alk P 0.6-2.7 times ULN], rapid resolution after stopping in all; 3 other cases had jaundice [bilirubin 17.5-39.7 mg/dL, ALT 11-77 times ULN, Alk P 1.5-4.5 times ULN, bilirubin 17.5-39.7 mg/dL], and slow resolution with minor ALT or GGT elevations persisting for more than a year after stopping).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R12">Desaint B, Conrad M, Florent C, Legendre C, Levy VG. [Is amodiaquine (Flavoquine) hepatotoxic?]. Gastroenterol Clin Biol 1986; 10: 440.  [<a href="/pubmed/3732752" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3732752</span></a>]<div><i>(Two cases of amodiaquine hepatotoxicity; 41 year old woman developed fatigue and jaundice 3 weeks after starting therapy [bilirubin 24.6 mg/dL, ALT 1700 U/L, Alk P 300 U/L], resolving within two months of stopping; 35 year old woman developed fatigue and abdominal pain [ALT 600 U/L] 3 months after starting amodiaquine, and was jaundiced and had ascites at 5 months [bilirubin 14.3 mg/dL, ALT 150 U/L, Alk P 213 U/L], requiring 4 months to resolve).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R13">Amouretti M, Raymond JM, Baldit C, Dumas F, Couzigou P, B&#x000e9;raud C. [Amodiaquine (Flavoquine) is hepatotoxic]. Gastroenterol Clin Biol 1986; 10: 855. French.  [<a href="/pubmed/3803831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3803831</span></a>]<div><i>(38 year old woman developed fatigue followed by jaundice 5 weeks after switching from chloroquine to amodiaquine [ALT 1136 U/L, bilirubin 8.8 mg/dL], with progression to hepatic failure and death; autopsy showed massive hepatic necrosis).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R14">Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J. Amodiaquine-induced agranulocytosis and liver damage. Br Med J 1986; 292: 721-3.  [<a href="/pmc/articles/PMC1339778/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1339778</span></a>] [<a href="/pubmed/3082410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3082410</span></a>]<div><i>(Seven cases of agranulocytosis [five with liver involvement] and 2 of liver damage due to amodiaquine seen between 1981-83; agranulocytosis arose 38-69 days after starting amodiaquine for malaria prophylaxis, persisting for 8-45 days, all had infectious complications leading to death in 2 patients; 2 with liver damage included a 55 year old man and a 36 year old woman who developed liver injury 42 and 120 days after starting amodiaquine [bilirubin 2.9 and 48.5 mg/dL, ALT 142 and 651 U/L, Alk P 126 and 166 U/L], one case fatal).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R15">Charmot G, Goujon C. [Minor hepatitis probably caused by amodiaquine]. Bull Soc Pathol Exot Filiales 1987; 80: 266-70.  [<a href="/pubmed/3608009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3608009</span></a>]<div><i>(8 patients, including 4 men and 4 women, ages 21-56 years, were found to have asymptomatic ALT elevations [86-577 U/L] without jaundice 25-300 days after starting amodiaquine, resolving within 1 week).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R16">St&#x000fc;rchler D, Sch&#x000e4;r M, Gyr N. Leucopenia and abnormal liver function in travelers on malaria chemoprophylaxis. J Trop Med Hyg 1987; 90: 239-43.  [<a href="/pubmed/3669125" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3669125</span></a>]<div><i>(Analysis of 451 travelers from Switzerland on malarial prophylaxis found higher ALT levels in those on amodiaquine than on chloroquine or no prophylaxis).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R17">Bernuau J, Larrey D, Campillo B, Degott C, Verdier F, Rueff B, Pessayre D, et al. Amodiaquine-induced fulminant hepatitis. J Hepatol 1988; 6:109-12.  [<a href="/pubmed/3346531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3346531</span></a>]<div><i>(3 patients, ages 12, 41 and 51 years, developed jaundice 4-10 months after starting amodiaquine prophylaxis [bilirubin 30.9, 31.6 and 10.5 mg/dL, ALT 13-47 times ULN, Alk P 1.8-2.2 times ULN], all dying of hepatic failure or requiring liver transplant; liver histology showed massive necrosis).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R18">Raymond JM, Dumas F, Baldit C, Couzigou P, Beraud C, Amouretti M. Fatal acute hepatitis due to amodiaquine. J Clin Gastroenterol 1989; 11: 602-3.  [<a href="/pubmed/2794450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2794450</span></a>]<div><i>(38 year old woman developed fatigue, dark urine and then jaundice 5 weeks after switching from chloroquine to amodiaquine [bilirubin 8.8 mg/dL, ALT 1,136 U/L], with rapid improvement on stopping but relapse 1 week after restarting [bilirubin 21.8 mg/dL, ALT 1010 U/L, Alk P 313 U/L] and progressive hepatic failure and death; autopsy showed massive hepatic necrosis).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R19">Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990; 83: 82-5.  [<a href="/pmc/articles/PMC1292502/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1292502</span></a>] [<a href="/pubmed/2138674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2138674</span></a>]<div><i>(Analysis of postmarketing adverse event reports on antimalarial drugs from UK sources; major problems were Stevens Johnson syndrome and agranulocytosis; serious hepatotoxicity occurred in 1:111,000 pyrimethamine-sulphadoxine, 1:75,200 pyrimethamine-dapsone, and 1:15,500 amodiaquine users; far fewer with chloroquine-proguanil).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R20">Clarke JB, Neftel K, Kitteringham NR, Park BK. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. Int Arch Allergy Appl Immunol 1991; 95: 369-75.  [<a href="/pubmed/1959977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1959977</span></a>]<div><i>(Amodiaquine antibodies found in 6 of 7 patients with adverse reaction and 7 of 22 without while on amodiaquine prophylaxis; reactivity not blocked by other aminoquinones).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R21">Orrell C, Taylor WR, Olliaro P. Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. Trans R Soc Trop Med Hyg 2001; 95: 517-8.  [<a href="/pubmed/11706664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11706664</span></a>]<div><i>(In a single dose crossover study in 15 volunteers, one developed rise in ALT from normal to peak of 483 U/L 6 weeks after dosing with amodiaquine and artesunate without symptoms or bilirubin rise, resolving in 4-8 weeks).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R22">Hirschel B. Questions about the antimalarial amodiaquine. Lancet 2003; 361: 1229; author reply 1229-30.  [<a href="/pubmed/12686075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12686075</span></a>]<div><i>(Letter questioning the advisability of using amodiaquine because of the risk of severe granulocytopenia; authors reply that the crisis of malaria and chloroquine resistance in Africa warrants use of amodiaquine for treatment, estimated fatality rate being 1:31,000 and severe hepatotoxicity as 1:15,650).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R23">Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27: 25-61.  [<a href="/pubmed/14720085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14720085</span></a>]<div><i>(Review of the toxicities and side effects of antimalarials; amodiaquine is linked to agranulocytosis and hepatitis in 1:2000 recipients).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R24">Sowunmi A, Fehintola FA, Adedeji AA, Gbotosho GO, Tambo E, Fateye BA, Happi TC, Oduola AM. Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children. Trop Med Int Health 2005; 10: 1161-70.  [<a href="/pubmed/16262741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16262741</span></a>]<div><i>(Controlled trial of 3 day regimens of artesunate-amodiaquine vs chloroquine-pyrimethamine-sulfadoxine in 153 children with malaria; &#x0201c;biochemical &#x02026; parameters remained normal before and after treatment in all subjects&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R25">Fanello CI, Karema C, van Doren W, Rwagacondo CE, D'Alessandro U. Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. Trop Med Int Health 2006; 11: 589-96.  [<a href="/pubmed/16640610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16640610</span></a>]<div><i>(Controlled trial of amodiaquine vs sulfadoxine/pyrimethamine vs both in 351 patients with malaria in Rwanda; ALT levels decreased during therapy and no mention of hepatotoxicity or hepatitis).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R26">Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT, Rosenthal PJ, Ouedraogo JB. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007; 369 (9560): 491-8.  [<a href="/pubmed/17292769" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17292769</span></a>]<div><i>(Controlled trial of artemether-lumefantrine vs sulfadoxine-pyrimethamine and amodiaquine in 521 patients with malaria; adverse event rates were similar and no mention of ALT levels or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R27">Markham LN, Giostra E, Hadengue A, Rossier M, Rebsamen M, Desmeules J. Emergency liver transplantation in amodiaquine-induced fulminant hepatitis. Am J Trop Med Hyg 2007; 77: 14-5.  [<a href="/pubmed/17620624" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17620624</span></a>]<div><i>(39 year old woman developed fatigue and then jaundice ~10 weeks after starting amodiaquine prophylaxis for malaria [bilirubin 14 mg/dL, ALT 1475 U/L, Alk P 108 U/L, protime 17%] and underwent successful liver transplant 6 days later; liver showed massive necrosis).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R28">Gasasira AF, Kamya MR, Achan J, Mebrahtu T, Kalyango JN, Ruel T, Charlebois E, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008; 46: 985-91.  [<a href="/pubmed/18444813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18444813</span></a>]<div><i>(Analysis of safety of artesunate and amodiaquine in children with malaria; ALT elevations occurred in less than 1%).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R29">Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya D, Nzarubara B, Talisuna AO, et al. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar 2008; 7: 106.  [<a href="/pmc/articles/PMC2441629/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2441629</span></a>] [<a href="/pubmed/18547415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18547415</span></a>]<div><i>(Controlled trial of 3 combination regimens in 382 children with malaria in Uganda; ALT elevations occurred in 0.5% with amodiaquine/artesunate, 0.3% with amodiaquine/sulfadoxine/pyrimethamine and 0.6% with artemether-lumefantrine).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R30">Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, Badoe EV, et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar 2008; 7: 127.  [<a href="/pmc/articles/PMC2478668/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2478668</span></a>] [<a href="/pubmed/18620577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18620577</span></a>]<div><i>(Controlled trial of artesunate-amodiaquine vs artemether-lumefantrice in 227 children with malaria in Ghana; similar efficacy; ALT levels improved during therapy and no reports of hepatitis or ALT increases).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R31">Sirima SB, Tiono AB, Gansan&#x000e9; A, Diarra A, Ou&#x000e9;draogo A, Konat&#x000e9; AT, Kiechel JR, et al. The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malar J 2009; 8: 48.  [<a href="/pmc/articles/PMC2662869/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2662869</span></a>] [<a href="/pubmed/19291301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19291301</span></a>]<div><i>(Controlled trial of fixed vs &#x0201c;loose&#x0201d; dose combinations of amodiaquine and artesunate in 750 children with P. falciparum malaria reported similar efficacy [92%] and safety, 7 [~1%] had ALT elevations, one child had levels &#x0003e;1000 U/L, but bilirubin levels were normal and there were no symptoms).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R32">Gu&#x000e9;vart E, Agu&#x000e9;mon A. [Two cases of fulminant hepatitis during a curative treatment with an artesunate-amodiaquine combination]. Med Mal Infect 2009; 39: 57-60. French.  [<a href="/pubmed/19013042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19013042</span></a>]<div><i>(Two cases of acute liver failure; 32 year old African given artesunate and amodiaquine for fever developed fatigue and anemia 3 days later with ALT 483 U/L and progressive hepatic failure; 44 year old African physician treated for fever with artesunate and amodiaquine developed fatigue after 3 and jaundice after 5 days with ALT 15,000 U/L and progressive hepatic failure).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R33">Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J 2009; 8: 125.  [<a href="/pmc/articles/PMC2698916/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2698916</span></a>] [<a href="/pubmed/19505304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19505304</span></a>]<div><i>(Controlled trial of artesunate-amodiaquine vs artemether-lumefantine for 3 days in 940 patients with malaria; response rates and side effects were similar in the two groups; rates of ALT elevations decreased during therapy and follow up, from 9% to 6%).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R34">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-404.  [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(313 cases of drug induced liver injury were seen over a 12 year period at a large hospital in Bangalore, India, none were attributed to antimalarials). </i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R35">Bojang K, Akor F, Bittaye O, Conway D, Bottomley C, Milligan P, Greenwood B. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One 2010; 5(6): e11225.  [<a href="/pmc/articles/PMC2888611/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2888611</span></a>] [<a href="/pubmed/20574538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20574538</span></a>]<div><i>(Controlled trial comparing 3 regimens for prevention of endemic malaria in 1008 Gambian children, 331 of whom received amodiaquine once monthly for 2-3 months; no severe adverse reactions were detected and no mention of liver injury, hepatitis or jaundice).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R36">Zwang J, Dorsey G, Djimd&#x000e9; A, Karema C, M&#x000e5;rtensson A, Ndiaye JL, Sirima SB, et al. Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa. Malar J 2012; 11: 260.  [<a href="/pmc/articles/PMC3468407/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3468407</span></a>] [<a href="/pubmed/22856598" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22856598</span></a>]<div><i>(Among 3113 patients treated with artesunate and amodiaquine for falciparum malaria in 8 controlled trials, common treatment emergent side effects were cough [33%], anorexia [17%], vomiting [15%], diarrhea [17%], pruritus [18%] and weakness [16%]; 4 patients [1%] developed jaundice, but no details provided).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R37">Thanh NX, Trung TN, Phong NC, Quang HH, Dai B, Shanks GD, Chavchich M, et al. The efficacy and tolerability of artemisinin-piperaquine (Artequick&#x000ae;) versus artesunate-amodiaquine (Coarsucam&#x02122;) for the treatment of uncomplicated plasmodium falciparum malaria in south-central Vietnam. Malar J 2012; 11: 217.  [<a href="/pmc/articles/PMC3411481/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3411481</span></a>] [<a href="/pubmed/22741618" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22741618</span></a>]<div><i>(Controlled trial comparing aremisinin with either piperaquine [n=63] for 2 days or with amodiaquine [65] for 3 days for falciparum malaria in Vietnam reported similar efficacy and tolerance; no severe adverse events reported and no mention of liver injury, jaundice or ALT elevations). </i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R38">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25. (In a. [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>population based study from Iceland, 96 cases of drug induced liver injury were identified over a 2 year period [2010 and 2011], but none were attributed to an antimalarial agent).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R39">Yeka A, Lameyre V, Afizi K, Fredrick M, Lukwago R, Kamya MR, Talisuna AO. Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children. PLoS One 2014; 9: e113311.  [<a href="/pmc/articles/PMC4249977/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4249977</span></a>] [<a href="/pubmed/25436614" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25436614</span></a>]<div><i>(Among 413 children with malaria treated with repeated courses of either artesunate-amodiaquine or artemether-lumefantrine over a 2 year period, both response and adverse event rates were similar with the 2 regimens, abnormal liver tests arising in 5.6% of children but were asymptomatic except in two children; nevertheless, all abnormalities resolved without specific treatment and did not recur despite readministration).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R40">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to an antimalarial agent).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R41">Advice for travelers. Treat Guidel Med Lett 2015: 57 (1466): 52-8.  [<a href="/pubmed/25853663" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25853663</span></a>]<div><i>(Concise guidelines on prevention of malaria in travelers; amodiaquine is not recommended for prophylaxis against malaria for travelers).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R42">Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, Belay K, et al. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis 2016; 213: 1134-42.  [<a href="/pmc/articles/PMC4836737/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4836737</span></a>] [<a href="/pubmed/26597254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26597254</span></a>]<div><i>(Among 602 Ugandan children with malaria treated with artesunate-amodiaquine or artemether-lumefantrine, adverse event rates were similar with the 2 regimens and there were no serious hepatic adverse events; no mention of ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R43">Coulibaly B, Pritsch M, Bountogo M, Meissner PE, Nebi&#x000e9; E, Klose C, Kieser M, et al. Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso. J Infect Dis 2015; 211: 689-97.  [<a href="/pubmed/25267980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25267980</span></a>]<div><i> (Among 221 children with falciparum malaria treated with artesunate-amodiaquine with or without methylene blue for 3 days, serious adverse events were uncommon and none were liver related; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Amodiaquine.R44">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, no cases were attributed to an antimalarial drug).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548404</span><span class="label">PMID: <a href="/pubmed/31643723" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643723</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Amlodipine/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Amoxapine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548404&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548404/?report=reader">PubReader</a></li><li><a href="/books/NBK548404/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548404" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548404" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Amodiaquine. [Updated 2017 Feb 2].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548404/pdf/Bookshelf_NBK548404.pdf">PDF version of this page</a> (120K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=amodiaquine+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Amodiaquine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=amodiaquine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Amodiaquine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4856816" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4856816" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4856816" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19013042" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Two cases of fulminant hepatitis during a curative treatment with an artesunate-amodiaquine combination].</a><span class="source">[Med Mal Infect. 2009]</span><div class="brieflinkpop offscreen_noflow">[Two cases of fulminant hepatitis during a curative treatment with an artesunate-amodiaquine combination].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Guévart E, Aguémon A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Med Mal Infect. 2009 Jan; 39(1):57-60. Epub 2008 Nov 13.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2868340" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria.</a><span class="source">[Lancet. 1986]</span><div class="brieflinkpop offscreen_noflow">Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR, Edwards G, Winstanley P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Lancet. 1986 Feb 22; 1(8478):411-4. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17620624" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Emergency liver transplantation in amodiaquine-induced fulminant hepatitis.</a><span class="source">[Am J Trop Med Hyg. 2007]</span><div class="brieflinkpop offscreen_noflow">Emergency liver transplantation in amodiaquine-induced fulminant hepatitis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Markham LN, Giostra E, Hadengue A, Rossier M, Rebsamen M, Desmeules J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Trop Med Hyg. 2007 Jul; 77(1):14-5. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8898036" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Systematic review of amodiaquine treatment in uncomplicated malaria.</a><span class="source">[Lancet. 1996]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Systematic review of amodiaquine treatment in uncomplicated malaria.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Lancet. 1996 Nov 2; 348(9036):1196-201. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12804382" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Amodiaquine for treating malaria.</a><span class="source">[Cochrane Database Syst Rev. 2003]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Amodiaquine for treating malaria.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Olliaro P, Mussano P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2003; (2):CD000016. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643723" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643723" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=6046763a4664552c1259c422">Amodiaquine - LiverTox</a><div class="ralinkpop offscreen_noflow">Amodiaquine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:08:43-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal102&amp;ncbi_phid=CE89ADD204652321000000000894028D&amp;ncbi_session=CE89ADD2046763A1_2196SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548404%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548404&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548404/&amp;ncbi_pagename=Amodiaquine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89ADD2046763A1_2196SID /projects/books/PBooks@9.2 portal102 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>